116 related articles for article (PubMed ID: 19909787)
1. Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.
De Bonis ML; Tessitore A; Pellecchia MT; Longo K; Salvatore A; Russo A; Ingrosso D; Zappia V; Barone P; Galletti P; Tedeschi G
Neurosci Lett; 2010 Jan; 468(3):287-91. PubMed ID: 19909787
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V
J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768
[TBL] [Abstract][Full Text] [Related]
3. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR
J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283
[TBL] [Abstract][Full Text] [Related]
4. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase.
Zhao WQ; Latinwo L; Liu XX; Lee ES; Lamango N; Charlton CG
Exp Neurol; 2001 Sep; 171(1):127-38. PubMed ID: 11520127
[TBL] [Abstract][Full Text] [Related]
5. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Camicioli RM; Bouchard TP; Somerville MJ
Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
[TBL] [Abstract][Full Text] [Related]
7. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
Müller T; Kuhn W
Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
[TBL] [Abstract][Full Text] [Related]
8. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
9. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Nissinen E
Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Müller T; Kuhn W
Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
[TBL] [Abstract][Full Text] [Related]
12. Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms.
Müller T
Int Rev Neurobiol; 2010; 95():49-71. PubMed ID: 21095459
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
[TBL] [Abstract][Full Text] [Related]
14. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
15. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
[TBL] [Abstract][Full Text] [Related]
16. Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers.
Fux R; Kloor D; Hermes M; Röck T; Proksch B; Grenz A; Delabar U; Bücheler R; Igel S; Mörike K; Gleiter CH; Osswald H
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F786-92. PubMed ID: 15855656
[TBL] [Abstract][Full Text] [Related]
17. L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease.
Isobe C; Abe T; Terayama Y
J Clin Neurosci; 2010 Jun; 17(6):717-21. PubMed ID: 20356746
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
[TBL] [Abstract][Full Text] [Related]
19. 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease.
Lin JJ; Yueh KC; Liu CS; Liu JT; Lin SZ
Acta Neurol Taiwan; 2007 Sep; 16(3):150-7. PubMed ID: 17966954
[TBL] [Abstract][Full Text] [Related]
20. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS
Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
